Application of Watson for Oncology in Hepatocellular Carcinoma Surgery
1 other identifier
observational
150
1 country
1
Brief Summary
The aim of this study was to evaluate the surgical decisions of Watson artificial intelligence in patients with hepatocellular carcinoma.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2017
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2017
CompletedFirst Submitted
Initial submission to the registry
April 4, 2019
CompletedFirst Posted
Study publicly available on registry
April 5, 2019
CompletedPrimary Completion
Last participant's last visit for primary outcome
December 31, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
December 31, 2021
CompletedApril 5, 2019
January 1, 2019
5 years
April 4, 2019
April 4, 2019
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Operative outcomes
Operative outcomes such as operative time, estimated blood loss and blood transfusion were recorded.
intraoperative
Secondary Outcomes (1)
Postoperative survival
3 years
Other Outcomes (1)
Disease-free survival
3 years
Study Arms (2)
Watson on oncology recommends surgery
Watson on oncology does not recommend surgery
Interventions
Watson on oncology surgery decision evaluation. The system acquires and evaluates a large amount of structured and unstructured data from previous medical records through machine learning and natural language processing, and USES algorithms to select treatment options as the best choice for a particular patient.
Eligibility Criteria
A total of 150 hepatocellular carcinoma patients admitted to the department of hepatobiliary surgery of zhujiang hospital of southern medical university from January 2017 to December 2021 were selected and divided into experimental group and control group
You may qualify if:
- years≤ Age ≤80 years
- Compling with the diagnosis criteria of complex hepatic carcinoma.
- Primary hepatic carcinoma without intrahepatic or extrahepatic extensive cancer metastasis, the metastatic hepatic carcinoma whose primary focal has been controlled
- Preoperative liver function is Child - Pugh grade A or B.
- The patients are volunteered for the study.
You may not qualify if:
- Patients with mental illness.
- Patients can't tolerate the operation owe to a variety of basic diseases (such as severe cardiopulmonary insufficiency, renal insufficiency, cachexia and blood system diseases, etc.)
- The patients refused to take part in the study.
- There are other co-existed malignant tumors.
- Benign liver diseases
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zhujiang Hospital of Southern Medical University
Guangzhou, Guangdong, 510282, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 4, 2019
First Posted
April 5, 2019
Study Start
January 1, 2017
Primary Completion
December 31, 2021
Study Completion
December 31, 2021
Last Updated
April 5, 2019
Record last verified: 2019-01